As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of InterCure Ltd. The largest reported stake is Alexander Rabinovich's, at 29.4%. One filing is on record since December 9, 2025 (Schedule 13D, December 9, 2025).
Sell to companies like InterCure Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
InterCure Ltd. has 1 Schedule 13D or 13G filing on record since 2025-12-09. 1 holder's latest filing reports 5% or more of ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 29.4% | 16,765,453 | SCHEDULE 13D, 2025-12-09 | 2025-03-02 |
Holding shares or following this stake? See who's behind InterCure Ltd. and the warning signs.
Free to see. No signup.
Watch InterCure Ltd.
Get an email when InterCure Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on InterCure Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on InterCure Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InterCure Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Alexander Rabinovich
The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Persons hold all securities of the Issuer for investment purposes only. The Ordinary Shares beneficially owned by the Reporting Persons were purchased in a series of investment transactions prior to the Issuer's initial public offering on the Nasdaq Global Market, and through the transactions described herein below, as well as acquisitions in the open market. Under the securities purchase agreement dated March 2, 2025 among the Issuer and certain investors, or the Private Placement, the Issuer issued to certain investors, including Mr. Rabinovich, (i) an aggregate of 7,349,896 Ordinary Shares, at a purchase price of NIS 4.83 (approximately $1.34) per ordinary share, at a premium above the opening price of the Ordinary Shares on the TASE on December 16, 2024, which was NIS 4.81 per share, or the Determining Date and (ii) warrants, or the Warrants, that have a term of four years, to purchase up to an additional 7,349,896 Ordinary Shares at an exercise price equal to NIS 5.70 (approximately $1.58), at an 18% premium above the opening price of the Ordinary Shares on the Determining Date, which may further increase the proceeds from the Private Placement up to a total of approximately NIS 77 million (approximately $21.5 million) if the Warrants are fully exercised for cash. The consideration for the allocated securities was determined through …The first part of Item 4 of the SCHEDULE 13D filed 2025-12-09; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-12-09 | Alexander Rabinovich | 29.4% | SCHEDULE 13D |
Also on the record for InterCure Ltd.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 19, 2026 | Form D, private offering | — | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for InterCure Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.